Overview
Dr. Villena’s main research interests lie in the field of Immuno-oncology and Immunotherapy. His previous research was on investigation of the tumor immune microenvironment and the development of T-cell‒mediated immunotherapy for thoracic malignancies. His current translational research is focusing on novel immunotherapy strategies for resectable lung cancer in preclinical models with immediate clinical applications.
Highlights
- 1The Journal of thoracic and cardiovascular surgery · 2022
- 2Journal of bronchology & interventional pulmonology · 2021
- 3European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
Publications
Funding
Active
5 grants- MPIAutologous Lymph Node T Cells Engineered to Overcome Treatment Resistant Lung CancerNational Cancer Institute · 2026–2028R21CA317270-01
- Co-IPICI Grant and Main Collaboration Agreement with Multiple SubprojectsParker Institute for Cancer Immunotherapy · 2024–2028PICI 235170-03
- PIExploiting a Clonal Archive of Tumor-Reactive T Cells in the Lymph Nodes to Overcome Treatment-Resistant Lung CancerGilead Sciences, Inc. · 2026–2028GS 255926-01
- PIGenetically engineered stem cell like T cells for the treatment of NSCLCAmerican Association for Thoracic Surgery · 2024–2026AATS 235502-02
- PIEvaluating Lymph Node T Cell "Clonal Replacement" in a Phase II Trial of Neoadjuvant SBRT plus Cemiplimab versus Chemotherapy plus Cemiplimab in Resectable NSCLCWCM Sandra and Edward Meyer Cancer Center · 2025–2026MCC CTIF 250906-01
Completed grants (5)
- PIT cells selected from lymph node acquisition for adoptive cell treatment of solid tumorsDaedalus Fund for Innovation (Weill Cornell) · 2024–2025BioPharma AllianceBP 242177-01
- PICharacterizing T cell PD-1 response in the tumor draining lymph nodes of early-stage NSCLC patientsInternational Association for the Study of Lung Cancer · 2023–2025IA 230418-02
- KPIntercepting progression from pre-invasive to invasive lung adenocarcinomaNational Cancer Institute · 2022–2025
- PITumor draining lymph node immunomodulation to decrease recurrence in NSCLCLUNGevity Foundation · 2022–2024LF 2022-13
- KPIntercepting progression from pre-invasive to invasive lung adenocarcinomaNational Cancer Institute · 2020–2021
Clinical research
Active
2 studies- PIAssociation Between PD-L1 Expression in Benign Regional Lymph Nodes and Response to Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung CancerWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIMechanism of T-cell memory differentiation in a lung cancer model and the role of PD-1 blockade on the tumor draining lymph nodes of NSCLC patientsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
News mentions
- Innovators Pitch Cell Therapies and AI Tools at Biomedical Innovation ChallengeJune 10, 2026
The eighth cohort of the Biomedical Innovation Challenge showcased its innovations and development plans during a lightning round of pitches and judges’ questions on June 4 in the Belfer Research Building.
- Inaugural Mastercard Pilot Grant Program Recipients SelectedApril 6, 2022
Five Weill Cornell Medicine faculty members have been awarded research funding from the Pilot Grant Program of the Mastercard Diversity-Mentorship Collaborative at Weill Cornell Medicine.
Media highlights
- Non-Smoker Shares Surprise Lung Cancer Diagnosis ExperienceSpectrum News NY1 · November 19, 2026
- Pope Leo's Cancer Prognosis Is 'Very Good,' According To Outside Medical ExpertsKPBS-TV (San Diego, CA) · October 15, 2026
- Pope Leo Has Lung Cancer, The Vatican SaysNPR · October 14, 2026
- Rib-Sparing Approach Lowers Post Thoracotomy PainTargeted Oncology · September 16, 2026
- Subcostal Robotic Surgery Cuts Thoracic PainTargeted Oncology · September 14, 2026
Mentoring
- MMMarissa MichaelMD mentee · Class of 2025
External relationships
Other
Intuitive Surgical, Inc